Cancer drug margins rebound despite 2019 price intervention
Cancer drug margins rebound despite price intervention
Cancer drug margins rebound despite price intervention
Pharma companies are exploring space-based manufacturing to grow drug crystals in microgravity, potentially improving cancer drug formulations. Companies such as Varda and BioOrbit are testing whether orbiting laboratories can make...
Drug prices are pushing public health care past the breaking point and some oncologists across Canada are blaming corporate greed. James Howard is paying $90,000 a month entirely out of pocket for a new pancreatic cancer medication from...
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody...
Red background with packaging for a Chinese lung cancer drug
The FDA rejected ivonescimab after its trial failed to show a statistically significant overall-survival benefit, despite delaying lung cancer progression in previously treated patients.
The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. (Madalina Vasiliu/The Epoch Times)
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational...
An experimental drug that breaks down a tumor's protective tissue wall made pancreatic cancer disappear in 75% of treated mice.
An experimental drug that breaks down a tumor's protective tissue wall made pancreatic cancer disappear in 75% of treated mice.
(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results...
The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.
The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework.
Regulatory approval is only the starting point: Pharmacists weigh clinical benefits, safety, trial relevance, and cost when deciding whether a cancer drug merits public funding. Medscape News Europe
Why Indias massive cancer drugs price drop may not benefit all
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial...
NPPA directs State drug controllers to strictly monitor prices
Erdafitinib, a cancer medication, is being misused by teens chasing height growth. Medical experts detail the severe risks of the heightmaxxing trend.
Various drugs, including Propranolol, are running low and a warning has been issued ahead of the winter months.
NPPA releases revised MRPs for 543 brands of anti-cancer medicines with the new prices effective from November 9; Jan Swasthya Abhiyan India (JSA India) says controlling trade margins alone is insufficient as life-saving cancer...
For cancer patients in India, the struggle to stay alive is as much about the disease as about the arithmetic of fighting it. Experts call the government’s price caps a tokenistic, short-term measure. Patients will not benefit unless...
The national drug price regulator warned that violations of revised MRPs will invite overcharging proceedings
(MedPage Today) -- Note that some links may require registration or subscription. CMS finalized its 2027 Physician Fee Schedule which aims to strengthen primary care, expand preventive services, reduce duplicate billing, and cut waste...
In the Nov 2 notification, the drug price regulator revised the ceiling price of oxaliplatin injection, a platinum-based chemotherapy drug used to treat colorectal and other gastrointestinal cancers
The findings raise questions about the extent to which the measure will bring down the cost of newer, patented cancer treatments.
Of the 397 brands whose price fell, 217 were at least twice as expensive as their revised price, and 120 were at least three times as expensive
The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the...
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
(MedPage Today) -- Note that some links may require registration or subscription. The parents of a 31-year-old software engineer with epilepsy who died in February sued OpenAI, claiming ChatGPT told the engineer to stop taking her...
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat Reuters